Overview

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults with Moderately Severe Crohn's Disease
Phase:
Phase 2
Details
Lead Sponsor:
Celgene Corporation
Treatments:
Lenalidomide